宫颈癌根治治疗后孤立性腹主动脉旁淋巴结复发的挽救治疗比较
该回顾性研究纳入50例宫颈癌根治治疗后首次诊断为孤立性腹主动脉旁淋巴结(PALN)复发的患者,比较放疗、同步放化疗(CCRT)、手术、化疗和最佳支持治疗(BSC)的结局。CCRT组3年总生存率85.7%,手术66.7%,化疗48.8%,放疗41.3%,BSC 0%(p=0.014);仅复发治疗方式与总生存显著相关。
要点
- CCRT组3年OS达85.7%,高于手术66.7%、化疗48.8%、放疗41.3%和BSC 0%。
- CCRT组3年局部控制率100%、无进展生存率71.4%,局部控制优于化疗和放疗。
- 复发治疗方式是唯一与总生存显著相关的因素(p=0.014)。
核心结论
- 尽管队列样本量小,结果提示CCRT可能有效预防PALN局部复发并改善总生存。
研究设计与样本
- 回顾性研究,纳入2002至2016年在本机构根治性治疗后首次诊断为孤立性PALN复发的50例宫颈癌患者。
- 初始根治治疗包括单纯放疗、CCRT或手术±术后放疗;中位随访33个月。
- 复发时中位年龄57岁(范围26-84岁),末次初始治疗至复发中位间隔10个月(范围1-91个月)。
主要发现
- 全部患者3年总生存率为47.0%。
- 复发后3年OS率:CCRT 85.7%、手术66.7%、化疗48.8%、放疗41.3%、BSC 0%(p=0.014)。
- 单因素分析显示仅复发治疗方式与OS显著相关。
- 3年局部控制率和PFS率:CCRT 100%和71.4%、手术100%和66.7%、化疗33.6%和13.7%、放疗55.5%和14.1%(LCR p=0.028,PFS p=0.059)。
- 转移灶数目、SCC-Ag水平和复发治疗方式与LCR显著相关;复发时年龄、SCC-Ag水平和转移灶数目与PFS显著相关。
关键数值与推荐
- 复发后3年OS率:CCRT 85.7%、手术66.7%、化疗48.8%、放疗41.3%、BSC 0%(p=0.014)。
- 复发后3年LCR:CCRT 100%、手术100%、化疗33.6%、放疗55.5%(p=0.028)。
- 复发后3年PFS率:CCRT 71.4%、手术66.7%、化疗13.7%、放疗14.1%(p=0.059)。
临床怎么用
- 对于宫颈癌根治治疗后孤立性PALN复发,CCRT可能作为优先考虑的挽救治疗选择。
- 复发时SCC-Ag水平和转移灶数目可用于辅助评估局部控制与无进展生存风险。
局限性
- 患者队列样本量小(50例),各治疗组例数少。
- 为单中心回顾性研究,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Some studies have demonstrated that concurrent chemo-radiotherapy is an effective salvage treatment for isolated para-aortic lymph node (PALN) recurrence. However, no studies have compared multi-treatment modalities, such as radiation therapy (RT), concurrent chemoradiotherapy (CCRT), surgery, chemotherapy, and best supportive care (BSC), across a sufficient number of patients with PALN recurrence. We thus aimed to evaluate the clinical outcomes of multi-treatment modalities for isolated PALN recurrence in uterine cervical cancer. METHODS: Records of 50 patients who were first diagnosed with isolated PALN recurrence after definitive cervical cancer treatment from 2002 to 2016 at our institution were reviewed retrospectively. The initial definitive cervical cancer therapies included RT alone, CCRT, or surgery with or without post-operative RT. The median follow-up time was 33 months. The median age at recurrence diagnosis was 57 years (range, 26-84 years). The median duration between the end of initial treatment and recurrence was 10 months (range, 1-91 months). The median maximum metastatic lesion size was 17 mm (range, 8-60 mm). Twenty-four patients had one or two PALN metastases, while 26 had 3 or more. Eighteen patients were treated for recurrence with RT alone, seven with CCRT, three with surgery, 17 with chemotherapy, and five with BSC. Potential prognostic factors included histopathology, initial FIGO stage, initial treatment, age at recurrence, tumor markers (serum SCC-Ag and CEA) at recurrence, time to recurrence, maximum size of the metastatic lesion, number of metastases, and the recurrence treatment method. RESULTS: The 3-year overall survival (OS) rates of all patients were 47.0%. The 3-year OS rate of patients who underwent CCRT for recurrence was 85.7%; surgery, 66.7%; chemotherapy, 48.8%; RT, 41.3%; and BSC, 0% (p = 0.014). Univariate analysis revealed that only the recurrence treatment method was significantly associated with OS. The 3-year local control rate (LCR) and progression free survival (PFS) rate for CCRT were 100 and 71.4%; for surgery, 100 and 66.7%; for chemotherapy, 33.6 and 13.7%; and for RT, 55.5 and 14.1%, respectively (LCR: p = 0.028, PFS: p = 0.059). The number of metastatic lesions, SCC-Ag levels and recurrence treatment method were significantly associated with LCR. Age at recurrence, SCC-Ag levels, and number of metastatic lesions were significantly associated with PFS. CONCLUSIONS: Although our patient cohort size was small, our results suggest that CCRT may be effective in preventing local disease recurrence in the PALN and may improve OS.
引用
- Kubota H, Tsujino K, Sulaiman NS, et al. Comparison of salvage therapies for isolated para-aortic lymph node recurrence in patients with uterine cervical cancer after definitive treatment. Radiat Oncol. 2019. PMID: 31878944. doi:10.1186/s13014-019-1442-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。